T. Rowe Price Investment Management, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,002,882 shares of CRNX stock, worth $34.8 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,002,882
Previous 1,068,532
6.14%
Holding current value
$34.8 Million
Previous $54.6 Million
6.09%
% of portfolio
0.03%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$315 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$241 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$216 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$213 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$188 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.86B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...